Sep 4, 2017   SOURCE: PR NewsWire

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021 with Bristol-Myers Squibb, Novartis, Pfizer & F. Hoffmann-La Roche Dominating

DUBLIN, September 4, 2017 /PRNewswire/ --

The "Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021" report has been added to Research and Markets' offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.

Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of GVHD treatment market as the market is completely based on off-label usage. These inorganic growth strategies include global merger and acquisition, partnerships and regional acquisition.

According to the report, one driver in the market is increased prevalence of cancer. Globally, cancer is one of the life-threating diseases. As per National Institutes of Health (NIH), it is the second largest cause of death globally. As per National Cancer Institute, in the US alone, 1,685,210 new cancer cases and 595,690 cancer deaths were expected during 2016. The prevalence of this disease is growing at high rates and is expected to grow at higher rates in future too. Bone marrow transplant is widely preferred in various types of cancers.

Further, the report states that one challenge in the market is off-label use of drugs. GVHD is one of the clinical disorders arising due to tissue and organ transplantation. It is more commonly observed in allogeneic transplants where the tissue or organ from another donor is transplanted into an individual. There is no specific drug indicated for GVHD, and thus the current management of GVHD is based on the off-label use of various drug therapies. This off-label use of drugs is one of the biggest challenges in the global GVHD treatment market till date.

Key vendors

    --  Bristol-Myers Squibb
    --  Novartis
    --  Pfizer
    --  F. Hoffmann-La Roche

Other prominent vendors

    --  Abbott
    --  AbbVie
    --  Allergan
    --  Anterogen
    --  Astellas Pharma
    --  Athersys
    --  Baxter
    --  Caladrius
    --  Cellular Biomedicine Group
    --  Cipla
    --  Eisai
    --  Eli Lilly
    --  GlaxoSmithKline
    --  Glenmark
    --  Helsinn Healthcare
    --  Heron Therapeutics
    --  Incyte Corporation
    --  IPCA Laboratories
    --  Kadmon Holdings
    --  Lupin
    --  Osiris Therapeutics
    --  RedHill
    --  Sanofi
    --  Shire
    --  Sun Pharmaceutical Industries
    --  Takeda Pharmaceutical

    --  ViaCyte

Key Topics Covered:

    1. Executive Summary
    2. Scope Of The Report
    3. Research Methodology
    4. Introduction
    5. Disease Overview
    6. Market Overview
    7. Pipeline Landscape
    8. Market Segmentation By Disease Type
    9. Geographical Segmentation
    10. Decision Framework
    11. Drivers And Challenges
    12. Market Trends
    13. Vendor Landscape
    14. Key Vendor Analysis
    15. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/74bvb9/global_graft_vs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-graft-vs-host-disease-gvhd-treatment-market-2017-2021-with-bristol-myers-squibb-novartis-pfizer--f-hoffmann-la-roche-dominating-300513444.html

SOURCE Research and Markets